|
|
Volumn 10, Issue 4, 2004, Pages 304-311
|
|
2003: What lessons for European biotechnology?
|
|
Author keywords
Biotechnology; European; Fundraising; IPO; Licensing; Phase II
|
|
Indexed keywords
ATORVASTATIN;
CANCER VACCINE;
CARDIOVASCULAR AGENT;
ETC 216;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
UNCLASSIFIED DRUG;
ARTICLE;
BIOTECHNOLOGY;
CAPITAL;
CLINICAL TRIAL;
DRUG INDUSTRY;
DRUG MECHANISM;
EUROPE;
FINANCIAL MANAGEMENT;
HEALTH CARE COST;
HEALTH ECONOMICS;
HEART MUSCLE ISCHEMIA;
HUMAN;
MARKETING;
QUALITY CONTROL;
UNITED STATES;
|
|
EID: 3242691601
PISSN: 14628732
EISSN: None
Source Type: Journal
DOI: 10.1057/palgrave.jcb.3040087 Document Type: Article |
|
Times cited : (3)
|
|
References (0)
|
